Hari Anant Deshpande, MD

Associate Professor of Medicine (Medical Oncology)

Clinical Interests

  • Medical Oncology
  • Sarcoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center: Endocrine Cancers Program | Head and Neck Cancers Program | Prostate and Urologic Cancers Program

General Adult Urology

Medical Oncology

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

  • Medical Oncology AB of Internal Medicine (1999)

Clinical Trials

Conditions Study Title
Prostate Detection of ARv7 in the plasma of men with advanced metastatic castrate resistant prostate cancer
Larynx, Lip, Oral Cavity and Pharynx EA3132: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV SCCHN
Soft Tissue Phase II Study of MLN0128 vs. Pazopanib
Bones and Joints, Pediatrics Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Prostate A Phase I/II Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in mCRPC
Prostate VT-464 in Patients W/Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Bladder WO29636: IMvigor 010 Study: Anti-(PD-L1) Antibody MPDL3280A Treatment vs. Versus Observation
Bladder S1314 (COXEN) with neoadjuvant therapy for localized, muscle invasive bladder cancer
Prostate, Phase I EC1169-01:Phase I study of PSA Targeting Tubulysin Conjugate EC1169 in Patients with recurrent mCRPC
Larynx, Lip, Oral Cavity and Pharynx, Thyroid Study of Pembrolizumab (MK-3475) for 1st Line Tx of Recurrent/Metastatic Squamous Cell Ca of H&N
Bladder, Other Urinary JVDC 05 (RANGE): Ramucirumab Plus Docetaxel in Participants With Urothelial Cancer
Bladder, Other Urinary ML29725: Expanded access program for atezolizumab in metastatic urothelial cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Larynx, Lip, Oral Cavity and Pharynx, Phase I Ph I Study evaluating Safety, Tolerability, & Efficacy of MEDI4736 w/ Tremelimumab
Lip, Oral Cavity and Pharynx NRG-HN002: Testing less intensive treatment for selected low-risk patients with oropharyngeal cancer
Cervix Uteri, Corpus Uteri, Ovary Phase I/II Study of IMMU-132 in Epithelial Cancers
Other Endocrine System A091202: Efatutazone vs. Placebo in Pts With Previously Treated, Unresectable Myxoid Liposarcoma
Lip, Oral Cavity and Pharynx Individualized treatment for nasopharyngeal cancer based on the patient's DNA
Bladder S1011: Standard or Extended Pelvic Lymphadenectomy in Pts to have Surgery for Invasive Bladder Canc
Brain and Nervous System, Pediatrics Germ Cell Tumor Pediatric CIRB study

Edit this profile

Contact Info

Hari Anant Deshpande, MD
Patient Care Locations
Yale Cancer CenterSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th Floor

New Haven, CT 06511
View on map...
Smilow Cancer CareYale-New Haven Hospital Saint Raphael Campus
1450 Chapel Street, Ste Suite A

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208028
333 Cedar Street,

New Haven, CT 06520-8028